Evidence map›Paper›PMID 27575365›Full record

ArticleEnvironment international2016

A crossover-crossback prospective study of dibutyl-phthalate exposure from mesalamine medications and semen quality in men with inflammatory bowel disease.

Feiby L Nassan, Brent A Coull, Niels E Skakkebaek, Michelle A Williams, Ramace Dadd, Lidia Mínguez-Alarcón, Stephen A Krawetz, Elizabeth J Hait, Joshua R Korzenik, Alan C Moss and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Environment international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Dibutyl-phthalate exposure from mesalamine medications and serum thyroid hormones in men.International journal of hygiene and environmental health · 2019
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Feiby L NassanDepartment of Environmental Health, Harvard T. H. Chan School of Public Health, Boston, MA, USA. Electronic address: fen769@mail.harvard.edu.
Brent A CoullDepartment of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Niels E SkakkebaekUniversity Department of Growth and Reproduction, Rigshospitalet, Copenhagen, Denmark.
Michelle A WilliamsDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Ramace DaddDepartment of Environmental Health, Harvard T. H. Chan School of Public Health, Boston, MA, USA.
Lidia Mínguez-AlarcónDepartment of Environmental Health, Harvard T. H. Chan School of Public Health, Boston, MA, USA.
Stephen A KrawetzDepartment of Obstetrics & Gynecology, Center for Molecular Medicine & Genetics, Wayne State University, Detroit, MI, USA.
Elizabeth J HaitDivision of Gastroenterology, Children's Hospital Boston, Harvard Medical School, Boston, MA, USA.
Joshua R KorzenikDivision of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Alan C MossCenter for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Jennifer B FordDepartment of Environmental Health, Harvard T. H. Chan School of Public Health, Boston, MA, USA.
Russ HauserDepartment of Environmental Health, Harvard T. H. Chan School of Public Health, Boston, MA, USA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Vincent Obstetrics and Gynecology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Harvard University · USBeth Israel Deaconess Medical Center · USBoston Children's Hospital · USBrigham and Women's Hospital · USRigshospitalet · DKWayne State University · US

Funding

Translational Research Support CoreP30ES000002 · NIEHS · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI JAIME ELIZABETH HART · 1985 to 2026
$44.6M
QTL AND MICROARRAY MAPPING LEAD SENSITIVITY GENESR01ES012933 · NIEHS · WAYNE STATE UNIVERSITY · PI RUDEN, DOUGLAS M · 2004 to 2015
$3.4M
Crossover Study on Human Exposure to Phthalates and Male FertilityR01ES017285 · NIEHS · HARVARD SCHOOL OF PUBLIC HEALTH · PI HAUSER, RUSS B · 2010 to 2014
$2.4M
NIEHS NIH HHS P30 ES000002NIEHS NIH HHS R01 ES012933NIEHS NIH HHS R01 ES017285
6 · The paper itself

Abstract

backgroundPhthalates are widely used chemicals with ubiquitous exposure. Dibutyl-phthalate (DBP), a male reproductive toxicant in animals, is understudied in humans. Some mesalamine medications used to treat inflammatory bowel disease (IBD) have DBP in their coating, whereas other mesalamine formulations do not.

objectivesTaking advantage of differences in mesalamine formulations, we investigated whether high-DBP exposure from mesalamine medications was associated with decreased semen parameters.

methods73 men with IBD taking mesalamine participated in a crossover-crossback prospective study. Men taking non-DBP containing mesalamine at baseline i.e., background exposure, crossed-over for four months to high-DBP mesalamine and then crossed-back for four months to their non-DBP mesalamine (B1HB2-arm;Background1-High-Background2) and vice versa for men taking high-DBP mesalamine at baseline (H1BH2-arm;High1-Background-High2). Men provided up to six semen samples (2: baseline, 2: crossover and 2: crossback).

resultsWe estimated crossover, crossback and carryover effects using linear mixed models adjusted for abstinence time, age, season and duration on high-DBP mesalamine at baseline. Semen parameters in B1HB2-arm (26 men, 133 samples) decreased after high-DBP mesalamine exposure (crossover versus baseline), especially motility parameters, and continued to decrease further even after crossback to non-DBP mesalamine (crossback versus crossover). The cumulative carryover effect of high-DBP (crossback versus baseline) was a decrease of % total sperm motility by 7.61(CI:-13.1, -2.15), % progressive sperm motility by 4.23(CI:-8.05, -0.4) and motile sperm count by 26.0% (CI:-46.2%, 1.7%). However, H1BH2-arm (47 men, 199 samples) had no significant change during crossover or crossback.

conclusionsMen newly exposed to high-DBP mesalamine for four months had a cumulative reduction in several semen parameters, primarily sperm motility, that was more pronounced and statistically significant even after exposure ended for four months.

Indexed as

AdultAnti-Inflammatory Agents, Non-SteroidalCross-Over StudiesDibutyl PhthalateHumansInflammatory Bowel DiseasesMaleMesalamineMiddle AgedPhthalic AcidsProspective StudiesSeasonsSemenSemen AnalysisSperm CountSperm MotilityAnti-Inflammatory Agents, Non-SteroidalDibutyl PhthalateMesalaminephthalic acidPhthalic AcidsInflammatory bowel disease (IBD)MesalaminePhthalatesSemen quality

Identifiers

PMID27575365
PMCPMC5027995
OpenAlexW2508279422

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.